Love Hemp Group PLC Total Voting Rights (2542L)

TIDMLIFE

RNS Number : 2542L

Love Hemp Group PLC

30 December 2022

30 December 2022

Love Hemp Group plc

("Love Hemp", the "Group", or the "Company")

Total Voting Rights

In accordance with the FCA's Disclosure Guidance and Transparency Rules, as at 30 December 2022, the Company's issued share capital consists of 1,359,331,911 Ordinary Shares of GBP0.01, each with one voting right. The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of voting rights in the

Company   is   1,359,331,911. 

The above figure of 1,359,331,911 should be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

--ENDS--

For further information please visit: www.lovehempgroup.com or contact:

   Love Hemp Group                                           [phone] 
   Tony Calamita, CEO                                         [e-mail] 

About Love Hemp Group

Love Hemp Group is a brand-led consumer goods company focussed on health and wellness solutions for consumer use cases including sleep, pain, anxiety, stress and recovery. The Company is a pioneer in the UK-based premium high-quality CBD market, with over 40 products including oils, edibles, sprays, cosmetics and topicals. The Company's range of products are sold online across 70 websites and in over 2,000 stores including some of the biggest retailers in the UK, such as Holland & Barrett, Boots and Ocado. Listed on the Aquis Stock Exchange (AQSE: LIFE) the Company recently changed its name to Love Hemp Group plc, from World High Life, to better reflect its focus on supporting the "best in class" CBD brand as it embarks on a wider expansion of its core business and offering.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NEXEAXANALSAFFA

(END) Dow Jones Newswires

December 30, 2022 02:00 ET (07:00 GMT)